Compared to Estimates, Henry Schein (HSIC) Q1 Earnings: A Look at Key Metrics

05.05.26 15:30 Uhr

Werte in diesem Artikel
Aktien

74,00 EUR 1,00 EUR 1,37%

Indizes

PKT PKT

25.820,1 PKT 522,5 PKT 2,07%

7.440,4 PKT 86,4 PKT 1,18%

For the quarter ended March 2026, Henry Schein (HSIC) reported revenue of $3.37 billion, up 6.3% over the same period last year. EPS came in at $1.32, compared to $1.15 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.33 billion, representing a surprise of +1.15%. The company delivered an EPS surprise of +10.3%, with the consensus EPS estimate being $1.20.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Henry Schein performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Geographic Revenue- International Distribution and Value-Added Services- Dental: $900 million versus the four-analyst average estimate of $857.3 million. The reported number represents a year-over-year change of +12.8%.Geographic Revenue- International Distribution and Value-Added Services- Medical: $30 million compared to the $26.86 million average estimate based on four analysts. The reported number represents a change of +20% year over year.Geographic Revenue- U.S. Distribution and Value-Added Services: $1.91 billion compared to the $1.91 billion average estimate based on four analysts.Geographic Revenue- U.S. Distribution and Value-Added Services- Dental- Merchandise: $624 million versus $604.82 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.Net Sales- Global Specialty Products: $397 million versus $398.74 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.2% change.Net Sales- Global Technology: $173 million versus $173.27 million estimated by six analysts on average.Net Sales- Global Distribution and Value-Added Services: $2.84 billion compared to the $2.8 billion average estimate based on six analysts.Net Sales- Eliminations: $-41 million versus the six-analyst average estimate of $-40.66 million. The reported number represents a year-over-year change of +10.8%.Net Sales- Global Distribution and Value-Added Services- Global Dental: $1.77 billion versus the four-analyst average estimate of $1.7 billion.Net Sales- Global Distribution and Value-Added Services- Global Medical: $1.07 billion compared to the $1.09 billion average estimate based on four analysts.Geographic Revenue- International Distribution and Value-Added Services: $930 million compared to the $884.16 million average estimate based on four analysts.Net Sales- Global Distribution and Value-Added Services- Global Dental- Global Equipment: $417 million versus $411.03 million estimated by four analysts on average.View all Key Company Metrics for Henry Schein here>>>Shares of Henry Schein have returned -3.8% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Henry Schein und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Quelle: Zacks

Nachrichten zu Henry Schein Inc.

Analysen zu Henry Schein Inc.

DatumRatingAnalyst
30.05.2019Henry Schein UnderperformWolfe Research
08.11.2018Henry Schein OutperformBarrington Research
04.10.2018Henry Schein OutperformRobert W. Baird & Co. Incorporated
07.08.2018Henry Schein HoldStifel, Nicolaus & Co., Inc.
08.03.2018Henry Schein Equal WeightBarclays Capital
DatumRatingAnalyst
08.11.2018Henry Schein OutperformBarrington Research
04.10.2018Henry Schein OutperformRobert W. Baird & Co. Incorporated
07.08.2018Henry Schein HoldStifel, Nicolaus & Co., Inc.
08.12.2017Henry Schein BuyDeutsche Bank AG
07.11.2017Henry Schein HoldStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
08.03.2018Henry Schein Equal WeightBarclays Capital
07.11.2017Henry Schein Sector PerformRBC Capital Markets
19.09.2017Henry Schein Sector PerformRBC Capital Markets
15.03.2017Henry Schein HoldDeutsche Bank AG
14.10.2016Henry Schein NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
30.05.2019Henry Schein UnderperformWolfe Research
10.03.2005Update Henry Schein Inc.: SellBanc of America Sec.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Henry Schein Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen